BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 35608296)

  • 1. The Ability of Lipoprotein (a) Level to Predict Early Carotid Atherosclerosis Is Impaired in Patients With Advanced Liver Fibrosis Related to Metabolic-Associated Fatty Liver Disease.
    Wu T; Ye J; Shao C; Lin Y; Wang W; Feng S; Zhong B
    Clin Transl Gastroenterol; 2022 Jul; 13(7):e00504. PubMed ID: 35608296
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advanced fibrosis associates with atherosclerosis in subjects with nonalcoholic fatty liver disease.
    Chen Y; Xu M; Wang T; Sun J; Sun W; Xu B; Huang X; Xu Y; Lu J; Li X; Wang W; Bi Y; Ning G
    Atherosclerosis; 2015 Jul; 241(1):145-50. PubMed ID: 25988358
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced fibrosis of non-alcoholic steatohepatitis affects the significance of lipoprotein(a) as a cardiovascular risk factor.
    Konishi K; Miyake T; Furukawa S; Senba H; Kanzaki S; Nakaguchi H; Yukimoto A; Nakamura Y; Watanabe T; Koizumi Y; Yoshida O; Tokumoto Y; Hirooka M; Kumagi T; Abe M; Matsuura B; Hiasa Y
    Atherosclerosis; 2020 Apr; 299():32-37. PubMed ID: 32203743
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The impact of concomitant hepatitis C virus infection on liver and cardiovascular risks in patients with metabolic-associated fatty liver disease.
    Tsai PS; Cheng YM; Wang CC; Kao JH
    Eur J Gastroenterol Hepatol; 2023 Nov; 35(11):1278-1283. PubMed ID: 37773778
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease.
    Petta S; Wai-Sun Wong V; Bugianesi E; Fracanzani AL; Cammà C; Hiriart JB; Lai-Hung Wong G; Vergniol J; Wing-Hung Chan A; Giannetti A; Merrouche W; Lik-Yuen Chan H; Le-Bail B; Lombardi R; Guastella S; Craxì A; de Ledinghen V
    Am J Gastroenterol; 2019 Jun; 114(6):916-928. PubMed ID: 31169533
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Validation of conventional non-invasive fibrosis scoring systems in patients with metabolic associated fatty liver disease.
    Wu YL; Kumar R; Wang MF; Singh M; Huang JF; Zhu YY; Lin S
    World J Gastroenterol; 2021 Sep; 27(34):5753-5763. PubMed ID: 34629799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Metabolic associated fatty liver disease better identifying patients at risk of liver and cardiovascular complications.
    Cheng YM; Wang CC; Kao JH
    Hepatol Int; 2023 Apr; 17(2):350-356. PubMed ID: 36471232
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Low Lipoprotein(a) Levels Predict Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease.
    Meroni M; Longo M; Lombardi R; Paolini E; Macchi C; Corsini A; Sirtori CR; Fracanzani AL; Ruscica M; Dongiovanni P
    Hepatol Commun; 2022 Mar; 6(3):535-549. PubMed ID: 34677008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Red blood cell distribution width derivatives in alcohol-related liver cirrhosis and metabolic-associated fatty liver disease.
    Michalak A; Guz M; Kozicka J; Cybulski M; Jeleniewicz W; Lach T; Cichoż-Lach H
    World J Gastroenterol; 2022 Oct; 28(38):5636-5647. PubMed ID: 36304090
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Varied Relationship of Lipid and Lipoprotein Profiles to Liver Fat Content in Phenotypes of Metabolic Associated Fatty Liver Disease.
    Wu T; Ye J; Shao C; Li F; Lin Y; Ma Q; Wang W; Feng S; Zhong B
    Front Endocrinol (Lausanne); 2021; 12():691556. PubMed ID: 34899591
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Non-invasive prediction nomogram for predicting significant fibrosis in patients with metabolic-associated fatty liver disease: a cross-sectional study.
    Zhang F; Han Y; Mao Y; Zheng G; Liu L; Li W
    Ann Med; 2024 Dec; 56(1):2337739. PubMed ID: 38574396
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of diagnostic performance between FIB-4 and NFS in metabolic-associated fatty liver disease era.
    Park H; Yoon EL; Kim M; Lee J; Kim JH; Cho S; Jun DW; Nah EH
    Hepatol Res; 2022 Mar; 52(3):247-254. PubMed ID: 34841632
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Liver Fibrosis in Asians With Metabolic Dysfunction-Associated Fatty Liver Disease.
    Sohn W; Kwon HJ; Chang Y; Ryu S; Cho YK
    Clin Gastroenterol Hepatol; 2022 May; 20(5):e1135-e1148. PubMed ID: 34224877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolic-associated fatty liver disease in relation to site-specific and multiple-site subclinical atherosclerosis.
    Wang X; Zhang R; Man S; Lv J; Yu C; Yin J; Wang X; Deng Y; Wang B; Li L; Pang Y
    Liver Int; 2023 Aug; 43(8):1691-1698. PubMed ID: 37337780
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low thyroid function is associated with an increased risk of advanced fibrosis in patients with metabolic dysfunction-associated fatty liver disease.
    Fan H; Li L; Liu Z; Zhang P; Wu S; Han X; Chen X; Suo C; Cao L; Zhang T
    BMC Gastroenterol; 2023 Jan; 23(1):3. PubMed ID: 36604612
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of advanced hepatic fibrosis and comorbidity in metabolic dysfunction-associated fatty liver disease in Korea.
    Kim M; Yoon EL; Cho S; Lee CM; Kang BK; Park H; Jun DW; Nah EH
    Liver Int; 2022 Jul; 42(7):1536-1544. PubMed ID: 35338555
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metabolomics to identify fingerprints of carotid atherosclerosis in nonobese metabolic dysfunction-associated fatty liver disease.
    Shao C; Xu L; Lei P; Wang W; Feng S; Ye J; Zhong B
    J Transl Med; 2023 Jan; 21(1):12. PubMed ID: 36624524
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Nomenclature Dilemma of Metabolic Associated Fatty Liver Disease (MAFLD): Considerable Proportions of MAFLD Are Metabolic Healthy.
    Park H; Yoon EL; Kim M; Cho S; Nah EH; Jun DW
    Clin Gastroenterol Hepatol; 2023 Apr; 21(4):1041-1049.e3. PubMed ID: 35504562
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Novel metabolic classification for extrahepatic complication of metabolic associated fatty liver disease: A data-driven cluster analysis with international validation.
    Ye J; Zhuang X; Li X; Gong X; Sun Y; Wang W; Feng S; Wu T; Zhong B
    Metabolism; 2022 Nov; 136():155294. PubMed ID: 35995280
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Non-invasive screening, staging and management of metabolic dysfunction-associated fatty liver disease (MAFLD) in type 2 diabetes mellitus patients: what do we know so far ?
    Binet Q; Loumaye A; Preumont V; Thissen JP; Hermans MP; Lanthier N
    Acta Gastroenterol Belg; 2022; 85(2):346-357. PubMed ID: 35709779
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.